Tempus AI Inc.

10 hours ago · seekingalpha.com

Tempus AI remains a buy after a 60% rally, driven by robust oncology testing volumes and expanding data & applications revenue. Q2 oncology testing volumes grew 31% YoY, with MRD test volumes nearly doubling since Q4 2025, validating the Personalis acquisition. Data & applications segment led Q2 growth at 28%, with strong bookings and AI innovation positioning the company for long-term growth and margin expansion.

13 hours ago · marketbeat.com

Tempus AI NASDAQ: TEM Founder and CEO Eric Lefkofsky said the company's second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business.

2 days ago · defenseworld.net

Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Ryan Fukushima sold 700 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total value of $49,000.00. Following the completion of the transaction, the chief executive officer directly owned

2 days ago · defenseworld.net

Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) CAO Ryan Bartolucci sold 7,062 shares of the company's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $529,650.00. Following the transaction, the chief accounting officer directly owned 60,804 shares of the company's

4 days ago · invezz.com

Tempus AI stock continues its strong bull run and is now trading at its highest level since November last year. TEM jumped to $80, up 95% from its lowest level this year, with market capitalization above $14 billion.

4 days ago · zacks.com

Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

6 days ago · seekingalpha.com

Tempus AI, Inc. (TEM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

11 days ago · gurufocus.com

Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical inform

13 days ago · businesswire.com

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H's ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmati.